Show simple item record

AuthorHalabi, Reem
AuthorDakroub, Fatima
AuthorHaider, Mohammad Z.
AuthorPatel, Stuti
AuthorAmhaz, Nayef A.
AuthorReslan, Mohammad A.
AuthorEid, Ali H.
AuthorMechref, Yehia
AuthorDarwiche, Nadine
AuthorKobeissy, Firas
AuthorOmeis, Ibrahim
AuthorShaito, Abdullah A.
Available date2023-11-19T09:02:32Z
Publication Date2023-11-09
Publication NameCancers
Identifierhttp://dx.doi.org/10.3390/cancers15225339
CitationHalabi, R.; Dakroub, F.; Haider, M.Z.; Patel, S.; Amhaz, N.A.; Reslan, M.A.; Eid, A.H.; Mechref, Y.; Darwiche, N.; Kobeissy, F.; et al. Unveiling a Biomarker Signature of Meningioma: The Need for a Panel of Genomic, Epigenetic, Proteomic, and RNA Biomarkers to Advance Diagnosis and Prognosis. Cancers 2023, 15, 5339. https://doi.org/10.3390/cancers15225339
URIhttp://hdl.handle.net/10576/49480
AbstractMeningiomas are the most prevalent primary intracranial tumors. The majority are benign but can undergo dedifferentiation into advanced grades classified by World Health Organization (WHO) into Grades 1 to 3. Meningiomas’ tremendous variability in tumor behavior and slow growth rates complicate their diagnosis and treatment. A deeper comprehension of the molecular pathways and cellular microenvironment factors implicated in meningioma survival and pathology is needed. This review summarizes the known genetic and epigenetic aberrations involved in meningiomas, with a focus on neurofibromatosis type 2 (NF2) and non-NF2 mutations. Novel potential biomarkers for meningioma diagnosis and prognosis are also discussed, including epigenetic-, RNA-, metabolomics-, and protein-based markers. Finally, the landscape of available meningioma-specific animal models is overviewed. Use of these animal models can enable planning of adjuvant treatment, potentially assisting in pre-operative and post-operative decision making. Discovery of novel biomarkers will allow, in combination with WHO grading, more precise meningioma grading, including meningioma identification, subtype determination, and prediction of metastasis, recurrence, and response to therapy. Moreover, these biomarkers may be exploited in the development of personalized targeted therapies that can distinguish between the 15 diverse meningioma subtypes.
SponsorThe publication of this article was covered by Qatar National Library (QNL).
Languageen
PublisherMDPI
Subjectmeningioma
NF2 mutations
biomarker
miRNA
proteomics
TitleUnveiling a Biomarker Signature of Meningioma: The Need for a Panel of Genomic, Epigenetic, Proteomic, and RNA Biomarkers to Advance Diagnosis and Prognosis
TypeArticle Review
Issue Number22
Volume Number15
ESSN2072-6694
dc.accessType Open Access


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record